Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 114 Published: March 31, 2022 Report Code: GMDGDHC22027IDB

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

The Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development market research report provides an overview of the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects.

What are the targets of the Primary Biliary Cholangitis pipeline drugs market?

Some of the targets of the Primary Biliary Cholangitis pipeline drugs market are Peroxisome Proliferator Activated Receptor Alpha, Bile Acid Receptor, Peroxisome Proliferator Activated Receptor Gamma, Ileal Sodium/Bile Acid Cotransporter, NADPH Oxidase, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD, Peroxisome Proliferator Activated Receptor Delta, Adenosine Receptor A3, Catenin Beta, and Fibroblast Growth Factor Receptor 1.

Primary Biliary Cholangitis pipeline drugs market, by targets

Primary Biliary Cholangitis pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Primary Biliary Cholangitis pipeline drugs market?

Some of the mechanisms of action of the Primary Biliary Cholangitis pipeline drugs market are Peroxisome Proliferator Activated Receptor Alpha Agonist, Bile Acid Receptor Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, NADPH Oxidase 1 Inhibitor, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NADInhibitor, Peroxisome Proliferator Activated Receptor Delta Agonist, Adenosine Receptor A3 Antagonist, Catenin Beta 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Agonist.

Primary Biliary Cholangitis pipeline drugs market, by mechanisms of action

Primary Biliary Cholangitis pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Primary Biliary Cholangitis pipeline drugs market?

Some of the routes of administration in the Primary Biliary Cholangitis pipeline drugs market are oral, subcutaneous, and intravenous.

Primary Biliary Cholangitis pipeline drugs market, by routes of administrationc

Primary Biliary Cholangitis pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Primary Biliary Cholangitis pipeline drugs market?

The molecule types in the Primary Biliary Cholangitis pipeline drugs market are small molecule, subunit vaccine, synthetic peptide, enzyme, gene-modified cell therapy, monoclonal antibody, oligonucleotide, and recombinant protein.

Primary Biliary Cholangitis pipeline drugs market, by molecule types

Primary Biliary Cholangitis pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Primary Biliary Cholangitis pipeline drugs market?

Some of the key companies in the Primary Biliary Cholangitis pipeline drugs market are Zydus Lifesciences Ltd, Ascletis Pharma Inc, Dr. Falk Pharma GmbH, GenKyoTex SA, AbbVie Inc, Abcuro Inc, Albireo Pharma Inc, Alexion Pharmaceuticals Inc, Avolynt Inc, and Calliditas Therapeutics AB.

Primary Biliary Cholangitis pipeline drugs market, by key companies

Primary Biliary Cholangitis pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets

Peroxisome Proliferator Activated Receptor Alpha, Bile Acid Receptor, Peroxisome Proliferator Activated Receptor Gamma, Ileal Sodium/Bile Acid Cotransporter, NADPH Oxidase, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD, Peroxisome Proliferator Activated Receptor Delta, Adenosine Receptor A3, Catenin Beta, and Fibroblast Growth Factor Receptor 1
Mechanisms of Action Peroxisome Proliferator Activated Receptor Alpha Agonist, Bile Acid Receptor Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Ileal Sodium/Bile Acid Cotransporter Inhibitor, NADPH Oxidase 1 Inhibitor, NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NADInhibitor, Peroxisome Proliferator Activated Receptor Delta Agonist, Adenosine Receptor A3 Antagonist, Catenin Beta 1 Inhibitor, and Fibroblast Growth Factor Receptor 1 Agonist
Routes of Administration Oral, Subcutaneous, and Intravenous
Molecule Types Small Molecule, Subunit Vaccine, Synthetic Peptide, Enzyme, Gene-Modified Cell Therapy, Monoclonal Antibody, Oligonucleotide, and Recombinant Protein
Key Companies Zydus Lifesciences Ltd, Ascletis Pharma Inc, Dr. Falk Pharma GmbH, GenKyoTex SA, AbbVie Inc, Abcuro Inc, Albireo Pharma Inc, Alexion Pharmaceuticals Inc, Avolynt Inc, and Calliditas Therapeutics AB

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Other Diseases).
  • Reviews of pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Primary Biliary Cholangitis (Other Diseases) therapeutics and enlists all their major and minor projects.
  • Assessment of Primary Biliary Cholangitis (Other Diseases) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Other Diseases).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Other Diseases).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Other Diseases) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • AbbVie Inc

    Abcuro Inc

    Albireo Pharma Inc

    Alexion Pharmaceuticals Inc

    Ascletis Pharma Inc

    Avolynt Inc

    Calliditas Therapeutics AB

    CAMP4 Therapeutics Corp

    Chia Tai Tianqing Pharmaceutical Group Co Ltd

    Cour Pharmaceuticals Development Co Inc

    CymaBay Therapeutics Inc

    Dr. Falk Pharma GmbH

    Escient Pharmaceuticals Inc

    Future Medicine Co Ltd

    Genfit SA

    GenKyoTex SA

    GentiBio Inc

    Gilead Sciences Inc

    Hanmi Pharmaceuticals Co Ltd

    HighTide Therapeutics Inc

    Kissei Pharmaceutical Co Ltd

    Kowa Co Ltd

    MediGene AG

    Mirum Pharmaceuticals Inc

    NGM Biopharmaceuticals Inc

    Parvus Therapeutics Inc

    PRISM Pharma Co Ltd

    Selecta Biosciences Inc

    Shaanxi Micot Technology Co Ltd

    Suzhou Zelgen Biopharmaceutical Co Ltd

    Umecrine Cognition AB

    Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Overview

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Companies Involved in Therapeutics Development

AbbVie Inc

Abcuro Inc

Albireo Pharma Inc

Alexion Pharmaceuticals Inc

Ascletis Pharma Inc

Avolynt Inc

Calliditas Therapeutics AB

CAMP4 Therapeutics Corp

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Cour Pharmaceuticals Development Co Inc

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Escient Pharmaceuticals Inc

Future Medicine Co Ltd

Genfit SA

GenKyoTex SA

GentiBio Inc

Gilead Sciences Inc

Hanmi Pharmaceuticals Co Ltd

HighTide Therapeutics Inc

Kissei Pharmaceutical Co Ltd

Kowa Co Ltd

MediGene AG

Mirum Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Parvus Therapeutics Inc

PRISM Pharma Co Ltd

Selecta Biosciences Inc

Shaanxi Micot Technology Co Ltd

Suzhou Zelgen Biopharmaceutical Co Ltd

Umecrine Cognition AB

Zydus Lifesciences Ltd

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drug Profiles

A-3907 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ABC-008 – Drug Profile

Product Description

Mechanism Of Action

aldafermin – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASC-42 – Drug Profile

Product Description

Mechanism Of Action

AVO-1681 – Drug Profile

Product Description

Mechanism Of Action

bezafibrate SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

budesonide DR – Drug Profile

Product Description

Mechanism Of Action

History of Events

bulevirtide – Drug Profile

Product Description

Mechanism Of Action

CNP-104 – Drug Profile

Product Description

Mechanism Of Action

History of Events

elafibranor – Drug Profile

Product Description

Mechanism Of Action

History of Events

EP-547 – Drug Profile

Product Description

Mechanism Of Action

History of Events

golexanolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

HM-15211 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HTD-1801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LJ-2698 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MT-2004 – Drug Profile

Product Description

Mechanism Of Action

norursodeoxycholic acid – Drug Profile

Product Description

Mechanism Of Action

Oligonucleotides for Primary Biliary Cholangitis – Drug Profile

Product Description

Mechanism Of Action

pemafibrate – Drug Profile

Product Description

Mechanism Of Action

PRI-724 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Primary biliary cholangitis – Drug Profile

Product Description

Mechanism Of Action

Primary Biliary Cholangitis (PBC) – Drug Profile

Product Description

Mechanism Of Action

History of Events

PVT-201 – Drug Profile

Product Description

Mechanism Of Action

remogliflozin etabonate – Drug Profile

Product Description

Mechanism Of Action

History of Events

RhuDex – Drug Profile

Product Description

Mechanism Of Action

History of Events

saroglitazar – Drug Profile

Product Description

Mechanism Of Action

History of Events

seladelpar lysine – Drug Profile

Product Description

Mechanism Of Action

History of Events

setanaxib – Drug Profile

Product Description

Mechanism Of Action

History of Events

tiomolibdate choline – Drug Profile

Product Description

Mechanism Of Action

History of Events

TQA-3526 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ursodiol – Drug Profile

Product Description

Mechanism Of Action

History of Events

volixibat potassium – Drug Profile

Product Description

Mechanism Of Action

History of Events

ZG-5266 – Drug Profile

Product Description

Mechanism Of Action

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Discontinued Products

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: First patient randomized in pivotal TRANSFORM study with setanaxib

Feb 01, 2022: Liver Institute Northwest participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)

Dec 10, 2021: Zydus announces EPICS-III phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC

Nov 15, 2021: Gannex announces China NMPA approved phase II and III protocols of ASC42, an FXR agonist, for treatment of primary biliary cholangitis

Nov 15, 2021: CymaBay Therapeutics long-term open label study finds treatment with seladelpar for two years improves key liver biomarkers in patients with PBC

Nov 11, 2021: CymaBay Therapeutics to host post-AASLD key opinion leader webinar on seladelpar for primary biliary cholangitis

Nov 02, 2021: New clinical data on GENFIT’s investigational compound Elafibranor to be presented at AASLD The Liver Meeting

Nov 02, 2021: Pinnacle Clinical Research, PLLC participating in RESPONSE, a global phase 3 clinical research study evaluating an investigational therapy for the treatment of Primary Biliary Cholangitis (PBC)

Oct 01, 2021: CymaBay Therapeutics announces presentations at The Liver Meeting 2021

Sep 06, 2021: Gannex announces clinical trial application of ASC42, an FXR agonist, for treatment of primary biliary cholangitis accepted by China NMPA

Aug 09, 2021: Calliditas receives FDA Fast Track Designation for setanaxib in PBC

Jul 21, 2021: European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC)

Jun 24, 2021: Korea-US innovative bio-drug confirms the possibility of treating various rare liver diseases

Jun 23, 2021: Mirum Pharmaceuticals presents analyses from volixibat at the EASL International Liver Congress 2021

Jun 21, 2021: CymaBay Therapeutics presents positive PBC data at the International Liver Congress 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by AbbVie Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Abcuro Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Albireo Pharma Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Alexion Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Ascletis Pharma Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Avolynt Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Calliditas Therapeutics AB, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by CAMP4 Therapeutics Corp, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Cour Pharmaceuticals Development Co Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by CymaBay Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Dr. Falk Pharma GmbH, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Escient Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Future Medicine Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Genfit SA, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by GenKyoTex SA, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by GentiBio Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Gilead Sciences Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by HighTide Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Kissei Pharmaceutical Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Kowa Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by MediGene AG, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Mirum Pharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by NGM Biopharmaceuticals Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Parvus Therapeutics Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by PRISM Pharma Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Selecta Biosciences Inc, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Shaanxi Micot Technology Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Umecrine Cognition AB, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Pipeline by Zydus Lifesciences Ltd, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects, 2022

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Dormant Projects, 2022 (Contd..1)

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.